Antibody Levels, Age Linked to Infection Risk in Ocrevus-treated MS

Antibody Levels, Age Linked to Infection Risk in Ocrevus-treated MS

294878

Antibody Levels, Age Linked to Infection Risk in Ocrevus-treated MS

Lower antibody levels in the bloodstream and younger age are associated with a greater likelihood of infection in people with multiple sclerosis (MS) receiving Ocrevus (ocrelizumab) therapy, a study has found. “Our work adds to the body of literature detailing real-world outcomes in MS patients treated with [Ocrevus] and safety outcomes,” the study’s researchers wrote. “Our results highlight the need to monitor patients’ immunoglobulin profiles prior to commencing [treatment] and during the maintenance course.” The…

You must be logged in to read/download the full post.